Molecular Pharmacology (USA) Limited, (MPL-USA) is a public,...

Molecular Pharmacology (USA) Limited, (MPL-USA) is a public, biotechnology company (OTCBB: MLPH) dedicated to the discovery and development of analgesic and anti-inflammatory products based on the proprietary MPL-TL (tripeptofen) compound. MPL-TL, an oligopeptide, is a new key active ingredient that targets a different part of the pain and inflammation cascade than other analgesic/anti-inflammatory drugs. It is the first significant new topical analgesic discovery in nearly 50 years and will drive new products and opportunity in the $36.5 billion analgesia and anti-inflammatory industry. Delivered through the skin, analgesic products based on MPL-TL are expected to be fast acting with localized effects and minimal anticipated drug interactions or side effects .




MPL USA holds the exclusive worldwide rights to develop new and fast-acting analgesic and anti-inflammatory products based on MPL-TL . The parent product for MPL-TL has been used and tested for nearly two decades and has been shown to be fast acting , safe and effective